Large arrow graphic

inVentiv Health Communications Adds Global Digital Expertise to Dramatically Improve Physician-Patient Communications

Emma D’Arcy Joins inVentiv Health’s London Digital Team as Head of Participatory Medicine; Ben Atkins Joins Chandler Chicco Companies as Chief Digital Officer in the West

BURLINGTON, Mass. – October 9, 2013 – The global communications division of inVentiv Health, offering best-in-class clinical, commercial and consulting services, today announced the appointment of two social media veterans to address the dramatic changes taking place in the way patients and physicians communicate.

Emma D’Arcy has joined inVentiv Health Communications’ Digital+Innovation team in London as head of Participatory Medicine. Participatory Medicine is an emerging model of care that promotes health care professionals and patients working in full partnership, using contemporary communications channels to increase the patient’s participation in their health care decision making. D’Arcy will work with clients to apply principles of Participatory Medicine to increase the success of new product launches.

D’Arcy is a medical biochemist who is currently conducting research on the impact of social media on the practice of medicine. A seasoned writer with 18 years of experience in the pharmaceutical industry, she is a frequent speaker and organizer of patient-centric conferences and has been published widely on the impact of digital communications on health care.

Ben Atkins, located in Los Angeles, will co-lead the growing digital practice of Chandler Chicco Companies to drive innovation, best practices, and digital/social integration across Chandler Chicco’s agencies. Atkins’ focus is on designing social experiences that help brands and organizations promote behavior change, and through his work clients better integrate their digital initiatives across corporate, product, physician and patient communications.

Prior to Chandler Chicco Companies, Atkins was at Amgen, where he worked as corporate communications director of digital and social media. In this role, Atkins led oversight and execution of Amgen’s web strategy, including the use of measurable digital and social technologies. Atkins also held roles of increasing responsibility at Novartis, including head of news and social media communications and global pharma news manager.

“Patients today are supporting one another on social networks, and healthcare professionals are becoming increasingly engaged with mobile communications and social media,” said Robert Chandler, President, inVentiv Health Communications. “Connecting these stakeholders through digital and social channels is essential to facilitating meaningful interactions to improve patient outcomes.”

About inVentiv Health
inVentiv Health, Inc. is a leading global provider of best-in-class clinical, commercial and consulting services to the life sciences industry. inVentiv offers convergent services that accelerate the performance of companies working to improve human life. In 40 countries around the world, inVentiv’s 12,000 employees work with more than 550 pharmaceutical, biotech and device companies, as well as companies that see health as a central part of their mission. inVentiv Health, Inc. is privately owned by inVentiv Group Holdings, Inc., an organization sponsored by affiliates of Thomas H. Lee Partners, L.P., Liberty Lane Partners and members of the inVentiv management team. inVentiv Health helps clients transform promising ideas into commercial reality. For more information, visit

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause our performance to differ materially. These forward-looking statements reflect our current views about future events and are subject to risks, uncertainties and assumptions. We wish to caution readers that certain important factors may have affected and could in the future affect our actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. Such factors include, without limitation: the impact of our substantial level of indebtedness on our ability to generate sufficient cash to fulfill our obligations under our existing debt instruments or our ability to incur additional indebtedness; the impact of customer project delays and cancellations and our ability to sufficiently increase our revenues and manage expenses and capital expenditures to permit us to fund our operations; the impact of the consummation of any future acquisitions; the impact of any change in our ratings and the ratings of our debt securities on our relationships with customers, vendors and other third parties; the impact of any additional leverage we may incur on our ratings and the ratings of our debt securities; our ability to continue to comply with the covenants and terms of our senior secured credit facilities and to access sufficient capital under our credit agreement or from other sources of debt or equity financing to fund our operations; the impact of any default by any of our credit providers; our ability to accurately forecast costs to be incurred in providing services under fixed price contracts; our ability to accurately forecast insurance claims within our self- insured programs; the potential impact of pricing pressures on pharmaceutical manufacturers from future healthcare reform initiatives or from changes in the reimbursement policies of third-party payers; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; the potential impact of financial, economic, political and other risks, including interest rate and exchange rate risks, related to conducting business internationally; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operation, and achieve the resulting synergies; the resolution of purchase price adjustment disputes in connection with our recent acquisitions and related impacts; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our client base; our ability to comply with all applicable laws as well as our ability to successfully adapt to any changes in applicable laws on a timely and cost effective basis; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the possibility that client agreements will be terminated or not renewed; any potential impairment of goodwill or intangible assets; consolidation in the pharmaceutical industry; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing, including initiatives by our clients to perform services we offer internally; our ability to convert backlog into revenue; the potential liability associated with injury to clinical trial participants; the actual impact of the adoption of certain accounting standards; and our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance. Holders of our debt instruments are referred to reports provided to investors from time to time and the offering memoranda provided in connection with the issuance of our notes for further discussion of these risks and other factors.

To learn more about how inVentiv Health experts can help you, please contact us by clicking here.

Contact Us

inVentiv Health has been made aware of an internet scam targeting job seekers who have posted their resumes on job posting websites. Scammers are contacting applicants via email and purporting to represent inVentiv Health. Many of these scammers are using Gmail accounts and Google Hangouts to communicate with applicants. All correspondence with us comes from an internal employee with a valid email address. Anyone who suspects they have been solicited in this scam should contact the FBI at